| pubmed-article:7523547 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0530993 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0010806 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0486805 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:7523547 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:7523547 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7523547 | pubmed:dateCreated | 1994-11-21 | lld:pubmed |
| pubmed-article:7523547 | pubmed:abstractText | Recently, a new immunometric assay (Cyfra 21-1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21-1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21-1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21-1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05-2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra 21-1 were observed in patients with chronic hepatitis (positivity rate: 17/51-33.3%) and with pancreatitis (positivity rate 5/16-31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21-1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21-1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with squamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21-1 was observed from stage I to stage IV (53.9% vs 85.7%; Chi square: p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7523547 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7523547 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7523547 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7523547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7523547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7523547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7523547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7523547 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7523547 | pubmed:issn | 0393-6155 | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:CastellsCC | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:BombardieriEE | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:BelloliSS | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:CianettiAA | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:ArditSS | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:CorrealeMM | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:Bogi?LL | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:SeregniEE | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:BusettoAA | lld:pubmed |
| pubmed-article:7523547 | pubmed:author | pubmed-author:CanielloBB | lld:pubmed |
| pubmed-article:7523547 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7523547 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:7523547 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7523547 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7523547 | pubmed:pagination | 89-95 | lld:pubmed |
| pubmed-article:7523547 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:meshHeading | pubmed-meshheading:7523547-... | lld:pubmed |
| pubmed-article:7523547 | pubmed:articleTitle | Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial. | lld:pubmed |
| pubmed-article:7523547 | pubmed:affiliation | Istituto Tumori, Milano, Italy. | lld:pubmed |
| pubmed-article:7523547 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7523547 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7523547 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7523547 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:7523547 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7523547 | lld:pubmed |
